Skip to main content

Advertisement

SpringerLink
Log in

The role of mannose binding lectin on fever episodes in pediatric oncology patients

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

Despite significant changes in pediatric oncological therapy, mortality is still high, mainly due to infections. Complement system as an ancient immune defense against microorganisms plays a significant role in surmounting infections, therefore, deficiency of its components may have particular importance in malignancies. The present paper assesses the effect of promoter (X/Y) and exon 1 (A/0) polymorphisms of the MBL2 gene altering mannose binding lectin (MBL) serum level in pediatric oncological patients with febrile neutropenia. Furthermore, frequency distribution of MBL2 alleles in children with malignancies and age-matched controls was analysed. Fifty-four oncohematological patients and 53 children who had undergone pediatric surgery were enrolled into this retrospective study. No significant differences were found in the frequency of MBL2 alleles between the hemato-oncologic and control group. The average duration of fever episodes was significantly shorter (p = 0.035) in patients carrying genotypes (AY/AY and AY/AX) that encode normal MBL level, compared to individuals with genotypes associated with lower functional MBL level (AX/AX, AY/0, AX/0, or 0/0) (days, median (IQ range) 3.7(0–5.4) vs. 5.0(3.8–6.6), respectively). In conclusion, our data suggest that MBL2 genotypes may influence the course of febrile neutropenia in pediatric patients with malignancies, and may contribute to clarification of the importance of MBL in infections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Walport MJ (2001) Complement Second of two parts. N Engl J Med 344:1140–1144

    Article  CAS  PubMed  Google Scholar 

  2. Walport MJ (2001) Complement First of two parts. N Engl J Med 344:1058–1066

    Article  CAS  PubMed  Google Scholar 

  3. Neth O, Jack DL, Dodds AW, et al. (2000) Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 68:688–693

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Garred P (2008) Mannose-binding lectin genetics: from a to Z. Biochem Soc Trans 36:1461–1466

    Article  CAS  PubMed  Google Scholar 

  5. Garred P, Larsen F, Madsen HO, et al. (2003) Mannose-binding lectin deficiency–revisited. Mol Immunol 40:73–84

    Article  CAS  PubMed  Google Scholar 

  6. Bouwman, LH, Roep, BO & Roos, (2006) A Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum Immunol. 67:247–256.

  7. Ruskamp JM, Hoekstra MO, Rovers MM, et al. (2006) (2006) mannose-binding lectin and upper respiratory tract infections in children and adolescents: a review. Arch Otolaryngol Head Neck Surg 132:482–486

    Article  PubMed  Google Scholar 

  8. Koutsounaki E, Goulielmos GN, Koulentaki M, et al. (2008) Mannose-binding lectin MBL2 gene polymorphisms and outcome of hepatitis C virus-infected patients. J Clin Immunol 28:495–500

    Article  CAS  PubMed  Google Scholar 

  9. Garred P, S J,J, Quist L, et al (2003) Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 188:1394–1403

    Article  CAS  PubMed  Google Scholar 

  10. Schmiegelow K, Garred P, Lausen B, et al. (2002) Increased frequency of mannose-binding lectin insufficiency among children with acute lymphoblastic leukemia. Blood 100:3757–3760

    Article  CAS  PubMed  Google Scholar 

  11. Neth O, Hann I, Turner MW, et al. (2001) Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 358:614–618

    Article  CAS  PubMed  Google Scholar 

  12. Ghazi M, Isadyar M, Gachkar L, et al. (2012) Serum levels of mannose-binding lectin and the risk of infection in pediatric oncology patients with chemotherapy. J Pediatr Hematol Oncol 34:128–130

    Article  CAS  PubMed  Google Scholar 

  13. Horiuchi T, Gondo H, Miyagawa H, et al. (2005) Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCT. Genes Immun 6:162–166

    Article  CAS  PubMed  Google Scholar 

  14. Peterslund NA, Koch C, Jensenius JC, et al. (2001) Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 358:637–638

    Article  CAS  PubMed  Google Scholar 

  15. Vekemans M, Robinson J, Georgala A, et al. (2007) Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy. Clin Infect Dis 44:1593–1601

    Article  CAS  PubMed  Google Scholar 

  16. Frakking FN, Brouwer N, Dolman KM, et al. (2011) Mannose-binding lectin (MBL) as prognostic factor in paediatric oncology patients. Clin Exp Immunol 165:51–59

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Bergmann OJ, Christiansen M, Laursen I, et al. (2003) Low levels of mannose-binding lectin do not affect occurrence of severe infections or duration of fever in acute myeloid leukaemia during remission induction therapy. Eur J Haematol 70:91–97

    Article  PubMed  Google Scholar 

  18. Lausen B, Schmiegelow K, Andreassen B, et al. (2006) Infections during induction therapy of childhood acute lymphoblastic leukemia–no association to mannose-binding lectin deficiency. Eur J Haematol 76:481–487

    Article  CAS  PubMed  Google Scholar 

  19. Martinez-Lopez J, Rivero A, Rapado I, et al. (2009) Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide. Leuk Lymphoma 50:1283–1289

    Article  CAS  PubMed  Google Scholar 

  20. Rubnitz JE, Howard SC, Willis J, et al. (2008) Baseline mannose binding lectin levels may not predict infection among children with leukemia. Pediatr Blood Cancer 50:866–868

    Article  PubMed  Google Scholar 

  21. Zehnder, A, Fisch, U, Hirt, A, et al. (2009) prognosis in pediatric hematologic malignancies is associated with serum concentration of mannose-binding lectin-associated serine protease-2 (MASP-2). Pediatr Blood Cancer. 2009;53:53–57.

  22. Frakking FN, Israels J, Kremer LC, et al. (2011) Mannose-binding lectin (MBL) and the risk for febrile neutropenia and infection in pediatric oncology patients with chemotherapy. Pediatr Blood Cancer 57:89–96

    Article  CAS  PubMed  Google Scholar 

  23. Bang P, Laursen I, Thornberg K, et al. (2008) (2008) the pharmacokinetic profile of plasma-derived mannan-binding lectin in healthy adult volunteers and patients with Staphylococcus aureus septicaemia. Scand J Infect Dis 40:44–48

    Article  CAS  PubMed  Google Scholar 

  24. Frakking FN, Brouwer N, van de Wetering MD, et al. (2009) Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaenia. Eur J Cancer 45:505–512

    Article  CAS  PubMed  Google Scholar 

  25. Valdimarsson H (2003) Infusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humans. Biochem Soc Trans 31:768–769

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by Együtt a Leukémiás Gyermekekért Alapítvány (Together for Children with Leukemia Foundation) and Gyermekonkológia Fejlesztéséért Alapítvány (Foundation for Development of Pediatric Oncology).

Conflict of Interest

The author(s) declare that they have no conflict interests.

Author information

Authors and Affiliations

  1. Department of Hematology, Heim Pál Children’s Hospital, Madarász Street Building, Madarász utca 22-24, Budapest, 1131, Hungary

    Ferenc Fekete & Brigitta Müller

  2. Department of Pediatric Surgery and Traumatology, Heim Pál Children’s Hospital, Budapest, Hungary

    Balázs Fadgyas

  3. National Institute of Psychiatry and Addictions, Gyula Nyírő Hospital, Budapest, Hungary

    Éva Papp

  4. 3rd Department of Internal Medicine, Research Laboratory, Semmelweis University, Budapest, Hungary

    Ágnes Szilágyi & Zoltán Prohászka

  5. 2nd Department of Pediatrics, Hematology Unit, Semmelweis University, Budapest, Hungary

    Gábor Kovács

Authors
  1. Ferenc Fekete
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Balázs Fadgyas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Éva Papp
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ágnes Szilágyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zoltán Prohászka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Brigitta Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gábor Kovács
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ferenc Fekete.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fekete, F., Fadgyas, B., Papp, É. et al. The role of mannose binding lectin on fever episodes in pediatric oncology patients. Pathol. Oncol. Res. 22, 139–143 (2016). https://doi.org/10.1007/s12253-015-9992-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-015-9992-x

Keywords

Search

Navigation